Results 31 to 40 of about 5,401 (177)

Exogenous Indian hedgehog antagonist damages intervertebral discs homeostasis in adult mice

Journal of Orthopaedic Translation, 2022
Background: Vismodegib, as an exogenous Indian hedgehog (Ihh) antagonist, has been approved by the Food and Drug Administration (FDA) for the clinical treatment of patients with basal cell carcinoma, and previous observations implicate the potential ...
Ran Chen, Ya Tan, Yang Li, Junlan Huang, Liang Kuang, Zhenhong Ni, Haiyang Lan, Rui Long, Yangli Xie, Hangang Chen, Xiaoqing Luo, Lin Chen, Ying Tang, Siru Zhou   +13 more
doaj   +1 more source

Gli1 expression in post-vismodegib excision samples.

, 2022
Gli1 expression in post-vismodegib excision samples.
Shelby P. Unsworth (8748393), Christopher A. Andrews (14204716), May P. Chan (14204719), Alon Kahana (197271), Curtis J. Heisel (8748390), Emily A. Eton (14204713), Christina F. Tingle (8748387), Scott C. Bresler (14204722)   +7 more
core   +1 more source

An alternative method for the preparation of vismodegib: A tool for an undergraduate laboratory course

Journal of Chemical Research, 2023
Vismodegib is the first hedgehog signaling pathway inhibitor approved by the Food and Drug Administration (FDA) for the treatment of basal-cell carcinoma.
Xuefei Bao, Chuqiao Song, Dan Liu, Guoliang Chen   +3 more
doaj   +1 more source

Keratin 5 expression in post-vismodegib excision samples.

, 2022
Keratin 5 expression in post-vismodegib excision samples.
Shelby P. Unsworth (8748393), Christopher A. Andrews (14204716), May P. Chan (14204719), Alon Kahana (197271), Curtis J. Heisel (8748390), Emily A. Eton (14204713), Christina F. Tingle (8748387), Scott C. Bresler (14204722)   +7 more
core   +1 more source

Long-Term Efficacy of Vismodegib After its Withdrawal and Patients’ Health-Related Quality of Life Using the Dermatology Life Quality Index (DLQI)

Dermatology and Therapy, 2019
Introduction Although non-melanoma skin cancers (NMSCs) are associated with a very low mortality risk, they have been reported to have a major impact on patients’ health-related quality of life (HRQoL).
Alessia Villani, Matteo Megna, Gabriella Fabbrocini, Milena Cappello, Maria Antonietta Luciano, Claudia Costa, Massimiliano Scalvenzi   +6 more
doaj   +1 more source

Vismodegib treatment enriches for cells with resistant mutations.

, 2022
A) Clinical photos and Gli1 expression (brown dots) in a patient pre- (left panels), post-vismodegib (center panels), and after recurrence (right panels), B) Allele frequency of PTCH1 and SMO variants pre-, post-vismodegib, and after recurrence (*variant
Shelby P. Unsworth (8748393), Christopher A. Andrews (14204716), May P. Chan (14204719), Alon Kahana (197271), Curtis J. Heisel (8748390), Emily A. Eton (14204713), Christina F. Tingle (8748387), Scott C. Bresler (14204722)   +7 more
core   +1 more source

Eight years of experience with vismodegib for advanced and multiple basal cell carcinoma patients in the Netherlands:a retrospective cohort study [PDF]

, 2021
BACKGROUND: Vismodegib has been used for the treatment of locally advanced basal cell carcinoma (laBCC) and metastatic BCC (mBCC) since 2011. Most efficacy and safety data are provided by clinical trials.
Devriese, Lot A, Mosterd, K, Aarts, M.J.B., Reinders, M, Racz, Emoke, Alers, R.J., Verkouteren, Babette J. A., Racz, E., Bekkenk, Marcel W, Kapiteijn, E, Reyners, AKL, Aarts, MJB, Nelemans, P., Reyners, An K L, Devriese, Lot A., Bekkenk, M.W., van Doorn, Remco, Verkouteren, B.J.A., Bekkenk, MW, Mosterd, Klara, Devriese, LA, Aarts, Maureen J B, Alers, RJ, Devriese, L.A., van Doorn, R., Kapiteijn, Ellen, Alers, Robert-Jan, Bekkenk, Marcel W., Terra, J.B., Mosterd, K., Verkouteren, BJA, Terra, Jorrit B., Terra, JB, Racz, Emoke; id_orcid, Kapiteijn, E., Terra, Jorrit B, Reinders, Marie G H C, Aarts, Maureen J. B., Wakkee, M., Reyners, An K. L., Doorn, R. van, Reyners, An K. L.; id_orcid, Reyners, A.K.L., Wakkee, Marlies, Nelemans, Patty, van Doorn, R, Reinders, M.G.H.C., Reinders, Marie G. H. C., Nelemans, P, Verkouteren, Babette J A   +49 more
core   +1 more source

Vismodegib as Novel Treatment of Periocular Basal Cell Carcinoma: A Mini Review [PDF]

, 2020
Basal cell carcinoma (BCC) is the most common cancer in the world. This study aims to review vismodegib treatment in BCC patients. Vismodegib has been approved for the treatment of adults with mBCC, or with laBCC that has recurred after surgery or who ...
Hendrian Dwikoloso Soebagjo
core   +1 more source

Vismodegib: the Proof of Concept in Basal Cell Carcinoma

, 2014
Although basal cell carcinoma (BCC) is the most common cancer worldwide, its metastatic dissemination is exceptional. Before 2012, we had a few treatment options available for metastatic or locally advanced cases.
Siham Lkhoyali, Narjiss Berrada, Hassan Errihani, Hind Mrabti   +3 more
core   +1 more source

Vismodegib-Induced Alopecia: Trichoscopic and Confocal Microscopy Evaluation

, 2020
Introduction: Vismodegib is the first-in-class inhibitor of the sonic hedgehog pathway useful in the treatment of locally advanced or metastatic basal cell carcinoma (BCC) that is not amenable to surgery and radiation therapy.
Patri A., Cappello M., Vastarella M., Fabbrocini G., Scalvenzi M., Cantelli M.   +5 more
core   +1 more source